anti-GARP CAR T cell therapy / The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) - LARVOL DELTA

Targeting TGFβ docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma. (PubMed, Neuro Oncol) - P1 | "GARP-LTGFβ plays a key role in the development and prognostics of GBM and GARP-targeted CAR-T therapy shows promising efficacy and safety in murine orthotopic GBM models. A first-in-human phase I clinical trial for patients with recurrent GBM began to enroll patients in May 2025 (NCT06964737)."

IO biomarker • Journal • Brain Cancer • Breast Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • TGFB1

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Ohio State University Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Anaplastic Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor